CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 528 enrolled
Drug / intervention
Aripiprazole oral productdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03179787
NCT03179787N/ACompleted

Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

Otsuka Pharmaceutical Co., Ltd.·observational·Posted Jun 7, 2017·Updated Sep 16, 2021

In Brief

An observational study evaluating Aripiprazole oral product for Autism. Completed, enrolled 528 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of aripiprazole in patients with autism in the real world clinical setting in Japan.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAutism
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 7, 2017
Enrollment StartApr 1, 2017
Primary CompletionMar 17, 2020
Study CompletionJul 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.1 years ago

Interventions

Aripiprazole oral productdrug

oral administration of aripiprazole